Publisher of Iranian Journals and Conference Proceedings

Please waite ..
Publisher of Iranian Journals and Conference Proceedings
Login |Register |Help |عضویت کتابخانه ها
Paper
Title

Immunization against Pseudomonas aeruginosa using Alg-PLGA nano-vaccine

Year: 1400
COI: JR_IJBMS-24-4_008
Language: EnglishView: 255
This Paper With 7 Page And PDF Format Ready To Download

Buy and Download

با استفاده از پرداخت اینترنتی بسیار سریع و ساده می توانید اصل این Paper را که دارای 7 صفحه است به صورت فایل PDF در اختیار داشته باشید.
آدرس ایمیل خود را در کادر زیر وارد نمایید:

Authors

Saeid Azimi - Parseh Institute of Iran, Tehran, Iran
Leila Safari Zanjani - Department of Cellular and Molecular Biology, Zanjan Branch, Payame Noor of Zanjan, Zanjan, Iran

Abstract:

Objective(s): Pseudomonas aeruginosa is the bacterium that causes of pulmonary infection among chronically hospitalized patients. Alginate is a common surface antigen of P. aeruginosa with a constant structure that which makes it an appropriate target for vaccines. In this study, P. aeruginosa alginate was conjugated with to PLGA nanoparticles, and its immunogenicity was characterized as a vaccine.Materials and Methods: Alginate was isolated from a mucoid strain of P. aeruginosa and conjugated with to PLGA with˝ N-(۳-Dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride ˝= ˝EDAC˝ and N-Hydroxysuccinimide (NHS). Chemical characterization of prepared nano-vaccine was performed using FTIR Spectroscopy, Zetasizer, and Atomic Force Microscopy (AFM). The immunogenicity of this nano-vaccine was evaluated through intramuscular injection into BALB/c mice.  Four groups of mice were subjected to the injection of alginate–PLGA, and two weeks after the last administration step, opsonophagocytosis assay, IgG detection, challenge, and cytokine determination via ELISA were carried out.Results: Alginate-PLGA conjugation was corroborated by FTIR, Zetasizer, and AFM. The ELISA consequence showed that alginate was prospering in the instigation of the humoral immunity.The immunogenicity enhanced against the alginate-PLGA. Remarkably diminished bacterial titer in the spleen of the immunized mice posterior to challenge with PAO۱ strain in comparison with the  alginate alone and control groups.Conclusion: The bacterial burden in the spleen significantly decreased after the challenge (p <۰.۰۵). The opsonic activity was significantly increased in the alginate- PLGA group (p <۰.۰۵). 

Keywords:

Paper COI Code

This Paper COI Code is JR_IJBMS-24-4_008. Also You can use the following address to link to this article. This link is permanent and is used as an article registration confirmation in the Civilica reference:

https://civilica.com/doc/1186917/

How to Cite to This Paper:

If you want to refer to this Paper in your research work, you can simply use the following phrase in the resources section:
Azimi, Saeid and Safari Zanjani, Leila,1400,Immunization against Pseudomonas aeruginosa using Alg-PLGA nano-vaccine,https://civilica.com/doc/1186917

مراجع و منابع این Paper:

لیست زیر مراجع و منابع استفاده شده در این Paper را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود Paper لینک شده اند :

  •     1.    Pedersen SS, Kharazmi A, Espersen F, Hoiby N. ...
  •     2.    Lam J, Chan R, Lam K, Costerton JW. ...
  •     3.    Deretic V, Schurr MJ, Yu H. Pseudomonas aeruginosa, ...
  •     4.    Linker A, Jones RS. A new polysaccharide resembling ...
  •     5.    Hentzer M, Teitzel GM, Balzer GJ, Heydorn A, ...
  •     6.    Kong HS. Effect of over epressing rsm A ...
  •     7.    Oliver AM, Weir DM. The effect of Pseudomonas ...
  •     8.    Meshulam T, Obedeanu N, Merzbach D, Sobel JD. ...
  •     9.    Learn DB, Brestel EP, Seetharama S. Hypochlorite scavenging ...
  •     10.    Cabral DA, Loh BA, Speert DP. Mucoid Pseudomonas ...
  •     11.    Williams BJ, Dehnbostel J, Blackwell TS. Pseudomonas aeruginosa: ...
  •     12.    Krieg DP, Helmke RJ, German VF, Mangos JA. ...
  •     13.    Govan JRW, Deretic V. Microbial pathogenesis in cystic ...
  •     14.    Pier GB, DesJardin D, Grout M, Garner C, ...
  •     15.    Pier GB, Boyer D, Preston M, Coleman FT, ...
  •     16.    Theilacker C, Coleman FT, Mueschenborn S, Llosa N, ...
  •     17.    Cryz SJ, Fürer E, Que JU. Synthesis and ...
  •     18.    Kashef N, Behzadian-Nejad Q, Najar-Peerayeh S, Mousavi-Hosseini K, ...
  •     19.    Najafzadeh F, Shapouri R, Rahnema M, Azar SR, ...
  •     20.    Morita T, Sakamura Y, Horikiri Y, Suzuki T, ...
  •     21.    Doring G and Pier G B. Vaccines and ...
  •     22.    Hatano K, Boisot S, DesJardins D, Wright DC, ...
  •     23.    Knutson CA, Jeanes A. Determination of the composition ...
  •     24.    Ames P, DesJardins D, Pier GB. Opsonophagocytic killing ...
  •     25.    Holder IA. Pseudomonas immunotherapy: A historical overview. Vaccine  ...
  •     26.    Phennicie RT, Sullivan MJ, Singer JT, Yoder JA, ...
  •     27.    Skwarczynski M, Toth I. Recent advances in peptide-based ...
  •     28.    Danhier F, Ansorena E, Silva JM, Coco R, ...
  •     29.    Horsfall AC, Butler DM, Marinova L, Warden PJ, ...
  •     30.    Pappu BP, Borodovsky A, Zheng TS, Yang X, ...
  •     31.    Su B, Wang J, Wang X, Jin H, ...
  •     32.    Mata E, Igartua M, Patarroyo ME, Pedraz JL, ...
  •     33.    Baltimore RS, and Mitchell M. Immunologic investigation of ...
  •     34.    Cabral DA, Loh BA, and Speert DP. Mucoid ...
  •     35.    Heiby N, Andersen V, and Bendien G. Pseudomonas ...
  •     36.    Krieg DP, Helmke RJ, German RF, Mangos JA. ...
  •     37.    Oliver AM, and Welr DM. Inhibition of bacterial ...
  •     38.    Pier GB, Small GL, Warren HB. Protection against ...
  •     39.    Roychoudhury S, May TB, Gill JF, Singh SK, ...
  •     40.    Woods DE, Bass JA, JohansonWG, Staus DS. Role ...
  •     41.    Lind bery A A, Glycoprotein conjugate vaccines. Vaccines ...
  •     42.    Campodonico V L, et al. Efficacy of conjugate ...
  •     43.    Holst J. Properties and clinical performance of vaccines ...
  •     44.    Doig P, Smith SNR, Todd T, Irvin RT. ...
  •     45.    Speert DP. Host defenses in patients with cystic ...
  •     46.    Thomas BM, Shinabarger D, Romilla M, Janichi K, ...
  •     47.    Ciofu O and Tolker-Nielsen T. Tolerance and resistance ...
  •     48.    Tan Qi, Qing Ai, Qi XU, Fang Li, ...
  •     49.    Charles AMC, Daniela NP, Christophe P, Karina A.Serban ...
  •     50.    Anne M,Oliver M, Weir DM. The effect of ...
  •     51.    Alikhani Z, Salouti M, Ardestani MS. Synthesis and ...
  •     52.    Leonie EP, Subhra M, Kreutz M, Figdor CG. ...
  •     53.    Danielle AWM, Shanno L, Haughneg SMK, Miechael JWA, ...
  •     54.    Aleksander MG, Tracy H. The role of airway ...
  •     55.    Simhadri VR, Andersen JF, Calvo E, Choi Sc, ...
  •     56.    Skwarczynski M and Toth I. Peptid-based subunit nanovaccines. ...
  •     57.    Sekhon BS, Saluja V. Nanovaccine an overview. Int ...
  •     58.    Devitt A, Moffatto D, Raykandalia C, Capra JD, ...
  •     59.    Leventis PA, Grinstein S. The distribution and function ...
  •     60.    Mazeheri F, Breus O, Durdu S, Haus D, ...
  •     61.    Safari Zanjani L, Shapouri R, Dezfulian M, Mahdavi ...
  •     62.    Safari Zanjani L, Shapouri R, Dezfulian M, Mahdavi ...

Research Info Management

Certificate | Report | من نویسنده این مقاله هستم

اطلاعات استنادی این Paper را به نرم افزارهای مدیریت اطلاعات علمی و استنادی ارسال نمایید و در تحقیقات خود از آن استفاده نمایید.

Share this page

More information about COI

COI stands for "CIVILICA Object Identifier". COI is the unique code assigned to articles of Iranian conferences and journals when indexing on the CIVILICA citation database.

The COI is the national code of documents indexed in CIVILICA and is a unique and permanent code. it can always be cited and tracked and assumed as registration confirmation ID.

Support